Blood
Articles in this Issue
iMMune profiling comes of age
Nanobody treatment of von Willebrand disease
FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML
Abstract FLAG-IDA (fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubicin) with venetoclax shows promise as frontline pediatric acute myeloid leukemia therapy....
A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma
Abstract Older patients with diffuse large B-cell lymphoma (DLBCL) present unfavorable genetic and microenvironmental alterations. In this phase 2 trial, we assessed the efficacy a...
A pooled primate screen finds that MYD88-CD40 boosts CAR-T
Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemia
Abstract Acute myeloid leukemia (AML) is characterized by a low 5-year survival rate. Despite having many clinical metrics to assess patient prognosis, there remain opportunities t...
One lipid to predict them all
A bispecific nanobody for the treatment of von Willebrand disease type 1
Abstract von Willebrand disease (VWD) type 1 is a bleeding disorder characterized by a quantitative deficiency of functional von Willebrand factor (VWF). We designed a novel bispec...
Isatuximab for relapsed AL amyloidosis
Neri P, Ren L, Azab AK, et al. Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. <i>Blood.</i> 2011;117(23):6202-6213.
Lichtenstein DA, Schischlik F, Shao L, et al. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. <i>Blood.</i> 2021;138(24):2469-2484.
<i>NPM1</i> -mutated acute myeloid leukemia with marked erythroid and megakaryocytic differentiation
Restoring p53 wild-type conformation in <i>TP53</i> -Y220C–mutant acute myeloid leukemia
Abstract TP53-Y220C is a recurrent hot spot mutation in cancers and leukemias. It is observed predominantly in acute myeloid leukemia (AML)/myelodysplastic syndromes among hematolo...
A T-cell–based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy
Abstract Immunotherapy has transformed the treatment landscape of multiple myeloma (MM), a hematological cancer predominantly affecting older individuals. Yet, whether immune aging...
TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma
Abstract Bruton tyrosine kinase inhibitors (BTKis) and cell therapy have successfully been used to treat mantle cell lymphoma (MCL). However, therapy resistance inevitably emerges....
Pooled CAR-T screening in pig-tailed macaques identifies designs with enhanced proliferation, trafficking, and persistence
Abstract Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of B-cell malignancies; however, &gt;60% of patients relapse within 1 year, often due...
Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702)
Abstract Isatuximab is an immunoglobulin G1κ monoclonal antibody that binds with high affinity to CD38 expressed on plasma cells. Anti-CD38 antibodies have shown efficacy as monoth...